Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics.

ABSTRACT:

Objectives

Long-acting cabotegravir plus rilpivirine (CAB+RPV) offers an alternative to daily oral therapy, but real-world data in East Asia remain scarce. This study aims to evaluate the impact of CAB+RPV in people with HIV in Japan, focusing on virological outcomes, treatment continuation and inflammatory markers, providing valuable insight into the use of injectable regimens in clinical practice.

Methods

This multicentre retrospective study analysed routinely collected data from eight HIV centres in Japan on people with HIV who initiated CAB+RPV before January 2024. Virological, renal, inflammatory and lipid outcomes were assessed using follow-up laboratory data obtained through April 2025.

Results

Among 136 participants, over 95% maintained HIV RNA <50 copies/mL,

SUBMITTER: Adachi E 

PROVIDER: S-EPMC12579889 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature